Equity Profile

BMY

Bristol-Myers Squibb Company

Health CarePharmaceuticals$132.1B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Bristol-Myers Squibb Company (BMY) is a leading pharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. With a market cap of $132 billion, it plays a crucial role in the health care sector, particularly in oncology, immunology, and cardiovascular diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

$1.66

Revenue

Revenue growth reflects the company's ability to sell its products and is vital for assessing overall business health.

$12.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, exceeding expectations by 9.65%. The stock reacted positively, gaining 5.21% the following day.

Management Promises & Guidance

Continued focus on expanding its oncology portfolio.
Commitment to maintaining strong operational efficiency.
Plans to enhance pipeline development for new therapies.

Expectations

Wall Street Expectations

Analysts expect Bristol-Myers Squibb to report solid earnings this quarter, driven by strong demand for its key products. The consensus EPS of $1.66 suggests confidence in the company's ongoing performance.

Bull Case

If the company beats EPS estimates, it could signal strong sales growth and effective cost management, leading to a positive stock reaction.

Bear Case

A miss on EPS or revenue could raise concerns about market competition and pricing pressures, potentially leading to a negative stock response.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.66

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$12.4B

Revenue growth reflects the company's ability to sell its products and is vital for assessing overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.66?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.

What are the revenue expectations for key products this quarter?

Understanding revenue from key products will help assess the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Bristol-Myers has a strong track record of exceeding EPS estimates, with an 88% beat rate over the last eight quarters.

Recent trends in oncology treatments suggest increasing demand that may not be fully reflected in current estimates.

Key Risk

If revenue from key products comes in below $11.9 billion, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether the company can maintain its growth trajectory amid market challenges.

Bull Confirmed If

An EPS of $1.70 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.60 would raise concerns about sales and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.83%

Historical Avg

±5.4%

In line with history

The options market is pricing in a move of about 4.83%, indicating some uncertainty around the earnings report.

Options are pricing ±4.8% while BMY has averaged ±5.4% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (1.0M)P/C Ratio: 1.07Puts (2.8M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bristol-Myers Squibb beats expectations, history suggests a stock increase of around 4.21%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss on earnings could lead to a decline of about 5.81%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key oncology drugs.
2Any changes in guidance regarding future product launches.
3Insights into cost management strategies.
4Discussion on competitive pressures in the pharmaceutical market.
5Management's outlook on overall market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

$1.66

Revenue

Revenue growth reflects the company's ability to sell its products and is vital for assessing overall business health.

$12.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, exceeding expectations by 9.65%. The stock reacted positively, gaining 5.21% the following day.

Management Promises & Guidance

Continued focus on expanding its oncology portfolio.
Commitment to maintaining strong operational efficiency.
Plans to enhance pipeline development for new therapies.

Expectations

Wall Street Expectations

Bull Case

If the company beats EPS estimates, it could signal strong sales growth and effective cost management, leading to a positive stock reaction.

Bear Case

A miss on EPS or revenue could raise concerns about market competition and pricing pressures, potentially leading to a negative stock response.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.66

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$12.4B

Revenue growth reflects the company's ability to sell its products and is vital for assessing overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.66?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.

What are the revenue expectations for key products this quarter?

Understanding revenue from key products will help assess the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Bristol-Myers has a strong track record of exceeding EPS estimates, with an 88% beat rate over the last eight quarters.

Recent trends in oncology treatments suggest increasing demand that may not be fully reflected in current estimates.

Key Risk

If revenue from key products comes in below $11.9 billion, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether the company can maintain its growth trajectory amid market challenges.

Bull Confirmed If

An EPS of $1.70 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.60 would raise concerns about sales and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.83%

Historical Avg

±5.4%

In line with history

The options market is pricing in a move of about 4.83%, indicating some uncertainty around the earnings report.

Options are pricing ±4.8% while BMY has averaged ±5.4% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (1.0M)P/C Ratio: 1.07Puts (2.8M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bristol-Myers Squibb beats expectations, history suggests a stock increase of around 4.21%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss on earnings could lead to a decline of about 5.81%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key oncology drugs.
2Any changes in guidance regarding future product launches.
3Insights into cost management strategies.
4Discussion on competitive pressures in the pharmaceutical market.
5Management's outlook on overall market conditions.